Original Article
Hip Pelvis 2013; 25(2): 135-140
Published online June 1, 2013
https://doi.org/10.5371/hp.2013.25.2.135
© The Korean Hip Society
Etanercept Treatment in Ankylosing Spondylitis Hip Lesions
Correspondence to : Sang Won Moon, MD
Department of Orthopaedic Surgery, Haeundae Paik Hospital, College of Medicine, Inje University, 875 Haeundae-ro, Haeundae-gu, Busan 612-896, Korea
TEL: +82-51-797-0990 FAX: +82-51-797-0991
E-mail: moonsw1106@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose: To evaluate the efficacy of etanercept in patients with an ankylosing spondylitis hip lesion.
Materials and Methods: Between March 2008 and December 2011, this study evaluated 13 patients with hip lesions who were refractory to conventional therapy. The general improvement was evaluated by the Harris hip score, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), ESR, CRP, and complications.
Results: The mean Harris hip score changed from 55.6±3.4 to 87.2±4.3(P=0.01). The mean BASDAI/ BASFI decreased from 6.8±1.7/6.8±1.6 before treatment to 4.4±1.8(P=0.02)/4.3±1.1(P=0.02) after treatment. The mean ESR/CRP changed from 48.4±31.5/5.8±5.1 to 20.8±19.7(P=0.06)/3.1±4.2(P=0.03). No complications were encountered.
Conclusion: These results suggest that etanercept can induce significant pain improvement in most ankylosing spondylitis hip lesions.
Keywords Ankylosing spondylitis, Hip lesion, TNF antagonist, Etanercept
PDF
Standard view
Export citation
Share Article
Original Article
Hip Pelvis 2013; 25(2): 135-140
Published online June 1, 2013 https://doi.org/10.5371/hp.2013.25.2.135
Copyright © The Korean Hip Society.
Etanercept Treatment in Ankylosing Spondylitis Hip Lesions
Young-Chang Kim, MD, Sang Won Moon, MD
Department of Orthopaedic Surgery, Haeundae Paik Hospital, College of Medicine, Inje University, Busan, Korea
Correspondence to:Sang Won Moon, MD
Department of Orthopaedic Surgery, Haeundae Paik Hospital, College of Medicine, Inje University, 875 Haeundae-ro, Haeundae-gu, Busan 612-896, Korea
TEL: +82-51-797-0990 FAX: +82-51-797-0991
E-mail: moonsw1106@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Purpose: To evaluate the efficacy of etanercept in patients with an ankylosing spondylitis hip lesion.
Materials and Methods: Between March 2008 and December 2011, this study evaluated 13 patients with hip lesions who were refractory to conventional therapy. The general improvement was evaluated by the Harris hip score, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), ESR, CRP, and complications.
Results: The mean Harris hip score changed from 55.6±3.4 to 87.2±4.3(P=0.01). The mean BASDAI/ BASFI decreased from 6.8±1.7/6.8±1.6 before treatment to 4.4±1.8(P=0.02)/4.3±1.1(P=0.02) after treatment. The mean ESR/CRP changed from 48.4±31.5/5.8±5.1 to 20.8±19.7(P=0.06)/3.1±4.2(P=0.03). No complications were encountered.
Conclusion: These results suggest that etanercept can induce significant pain improvement in most ankylosing spondylitis hip lesions.
Keywords: Ankylosing spondylitis, Hip lesion, TNF antagonist, Etanercept
Previous Article
Article Tools
Stats or Metrics
Share this article on
Related articles in H&P
-
Long-term Outcomes of Cemented Total Hip Arthroplasty in Patients with Ankylosing Spondylitis at a Minimum Follow-up of 10 Years
Soo Jae Yim, MD, PhD, Yong Bok Park, MD, Junyoung Kim, MD, Sin Hyung Park, MD, PhD
Hip Pelvis 2018; 30(3): 175-181 -
Diagnosis and Treatment of Inflammatory Joint Disease
Yeesuk Kim, MD, Hyun-Cheol Oh, MD, Jang Won Park, MD, In-Sung Kim, MD, Jun-Young Kim, MD, Ki-Choul Kim, MD‖, Dong-Sik Chae, MD, Woo-Lam Jo, MD, Joo-Hyoun Song, MD
Hip Pelvis 2017; 29(4): 211-222 -
Medical Treatment of Ankylosing Spondylitis
Kyoung-Ho Moon, MD, PhD, Young-Tae Kim, MD
Hip Pelvis 2014; 26(3): 129-135
